Evidence map›Paper›PMID 42758835›Full record

ArticleScience advances2026

Functional diversity of natural human

Samira Schiefer, David Jones, Florence Kwaschik, Benjamin G Hale

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Samira SchieferInstitute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland.ORCID 0000-0001-9422-5646
David JonesInstitute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland.ORCID 0000-0002-4789-203X
Florence KwaschikInstitute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland.ORCID 0000-0002-9540-7991
Benjamin G HaleInstitute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland.ORCID 0000-0002-3891-9480

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human interferon-β (IFN-β), a type I IFN, is critical for effective innate immunity and is also an approved disease-modifying therapeutic. While genetic variations in several components of the type I IFN system are associated with infectious and immune diseases, consequences of

Indexed as

Genetic VariationImmunity, InnateInterferon-betaHumansReceptor, Interferon alpha-betaSignal TransductionIFNAR1 protein, humanIFNAR2 protein, humanInterferon-betaReceptor, Interferon alpha-beta

Identifiers

PMID42758835
PMCPMC13588187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.